Take Our PhysQuiz on ACR Convergence 2020! Mar 19, 2021 Test your knowledge on results on PsA released at ACR Convergence 2020 – take our quiz and see how you compare with your colleagues! 1) DMARD-naïve patients achieving Routine Assessment of Patient Index Data 3 (RAPID3) and the Clinical Disease Activity for Psoriatic Arthritis (cDAPSA) targets with apremilast (Otezla), showing early and sustained improvements after how long?* a) 52 weeks b) 32 weeks c) 24 weeks d) 16 weeks 2) In a study presented at ACR 2020, family history of psoriasis (odds ratio [OR] = 2.71, 95% confidence interval [CI] 1.24 – 5.90) and psoriasis severity (OR=1.96, 95% CI 1.26 -3.06) were more likely in those who had a delay in transition from psoriasis to PsA than those who had a concomitant diagnosis.* a) True b) False 3) 1) Data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2 showed that guselkumab (Tremfya) improved what in adult patients with active psoriatic arthritis (PsA) and maintained response through 52 weeks of active treatment?* a) Swollen joints b) Bone density c) Fatigue d) PsA disease activity 4) What drug is the first and only FDA-approved selective anti-IL-23 therapy for active psoriatic arthritis and the only therapy for psoriatic arthritis to have improvement in fatigue as measured by FACIT-F in the product label?* a) Ixekizumab b) Deucravacitinib (Talz) c) Guselkumab (Tremfya) d) None of the above CAPTCHA Author Mukuntha Subburayan View all posts